CASP1 and diabetic kidney disease: The targeting of the NLRP3 inflammasome (e.g., MCC950 and OLT1177), executioners of pyroptosis (e.g., VX-765, which targets caspase-1), key regulators of necroptosis (e.g., Necrostatin-1, which targets RIPK1, and GSK872, which targets RIPK3), and the process of ferroptosis (e.g., ferrostatin-1 and liproxstatin-1) has been shown to ameliorate various pathological features of DKD, including inflammation, fibrosis, podocyte loss, and tubular injury.